arrow
S

Shiji Fang

the fifth affiliated hospital of wenzhou medical university
H指数:26
被引数:2,419
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of Proximal Stent Placement Site on Postoperative Outcomes After TIPS: Hepatic Vein Versus Inferior Vena Cava

经颈静脉肝内门体分流术后近端支架放置位置对术后结局的影响:肝静脉与下腔静脉的比较

2026-08-060
PRE
Mitochondria-Targeted Nanomotor: H2S-Driven Cascade Therapy for Hepatocellular Carcinoma

线粒体靶向纳米马达:H2S驱动的级联疗法用于肝细胞癌

2025-12-010
OAAI
Tumor-Targeted FABP5/STING Cascade Promote Radiofrequency Ablation Induced Ferroptosis and Intratumoral Immune Rewiring in Hepatocellular Carcinoma

肿瘤靶向FABP5/STING级联促进射频消融诱导的铁死亡及肝癌内的肿瘤内免疫重编程

2025-09-160
OAAI
Magnesium microspheres for enhanced transarterial chemoembolization therapy of hepatocellular carcinoma: From animal models to a pilot clinical study

用于增强经动脉化疗栓塞治疗肝细胞癌的镁微球:从动物模型到一项初步临床研究

2025-07-040
PRE
Fangchinoline inhibits metastasis and reduces inflammation-induced epithelial-mesenchymal transition by targeting the FOXM1-ADAM17 axis in hepatocellular carcinoma (vol 124, 111467, 2024)
2025-03-010
PRE
Lactate-Fueled Theranostic Nanoplatforms for Enhanced MRI-Guided Ferroptosis Synergistic with Immunotherapy of Hepatocellular Carcinoma

乳酸供能的诊疗一体化纳米平台,用于增强MRI引导的 ferroptosis 与免疫治疗协同作用的肝细胞癌治疗

2025-02-040
PRE
MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies

MELK通过稳定FABP5,抑制射频消融诱导的免疫原性细胞死亡及抗肿瘤免疫反应,从而在肝细胞恶性肿瘤中发挥作用。

2025-01-271
OA
Fangchinoline inhibits metastasis and reduces inflammation-induced epithelial-mesenchymal transition by targeting the FOXM1-ADAM17 axis in hepatocellular carcinoma
2024-12-012
PRE
HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma (vol 284, 121512, 2022)
2024-12-010
PRE
Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope

肿瘤免疫微环境重塑和免疫治疗中的Cuproptosis,ferroptosis和PANoptosis: 罪魁祸首或新希望

2024-11-150
OAAI
Glycerophospholipid-driven lipid metabolic reprogramming as a common key mechanism in the progression of human primary hepatocellular carcinoma and cholangiocarcinoma
2024-10-013
OAAI
Potentiated Calcium Carbonate with Enhanced Calcium Overload Induction and Acid Neutralization Capabilities to Boost Chemoimmunotherapy against Liver Cancer

增强的碳酸钙具有增强的钙超载诱导和酸中和能力,以促进对肝癌的化学免疫疗法

2024-09-290
PRE
Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy
2024-07-052
OAAI
Acidic/hypoxia dual-alleviated nanoregulators for enhanced treatment of tumor chemo-immunotherapy
2024-04-012
OA
Multiple Immunomodulatory Strategies Based on Targeted Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Immune Homeostasis against Hepatocellular Carcinoma
2024-03-111
PRE
Self-targeted smart polyester nanoparticles for simultaneous Delivery of photothermal and chemotherapeutic agents for efficient treatment of HCC
2024-01-010
PRE
Mesenchymal stem cell-derived extracellular vesicles in skin wound healing: roles, opportunities and challenges

间充质干细胞来源的细胞外囊泡在皮肤创伤愈合中的作用、机遇与挑战

2023-08-1765
OAAI
MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent way
2023-07-178
OA
TACE responser NDRG1 acts as a guardian against ferroptosis to drive tumorgenesis and metastasis in HCC
2023-05-196
OAAI
Proteomic analysis of DZIP3 interactome and its role in proliferation and metastasis in gastric cancer cells
2023-04-010
PRE